西南国防医药
西南國防醫藥
서남국방의약
MEDICAL JOURNAL OF NATIONAL DEFENDING FORCES IN SOUTHWEST CHINA
2014年
11期
1194-1196
,共3页
程朋%何乾文%李东%高辉%陈滔%苏晓妹%李焱%许涛%张涛
程朋%何乾文%李東%高輝%陳滔%囌曉妹%李焱%許濤%張濤
정붕%하건문%리동%고휘%진도%소효매%리염%허도%장도
肝癌%微波消融%肝动脉%栓塞%化疗%疗效
肝癌%微波消融%肝動脈%栓塞%化療%療效
간암%미파소융%간동맥%전새%화료%료효
liver cancer%PMCT%TACE%chemotherapy%curative effect
目的探讨肝动脉栓塞化疗（ TACE）联合微波消融治疗（ PMCT）中晚期肝癌的临床疗效。方法选取我院2007年1月~2012年1月127例单发肿瘤直径5~8 cm的中晚期肝癌患者，分为TACE组32例和联合组（ TACE+PMCT）95例。治疗2个周期后，通过超声造影对两组治疗效果进行评估。结果联合组中49例（51.6%）肿瘤完全灭活，46例肿瘤灭活不全；而TACE组中8例（25.4%）肿瘤完全灭活，TACE组肿瘤完全灭活率显著低于联合组（ P<0.05）。结论 TACE联合PMCT治疗中晚期肝癌疗效优于单用TACE治疗。
目的探討肝動脈栓塞化療（ TACE）聯閤微波消融治療（ PMCT）中晚期肝癌的臨床療效。方法選取我院2007年1月~2012年1月127例單髮腫瘤直徑5~8 cm的中晚期肝癌患者，分為TACE組32例和聯閤組（ TACE+PMCT）95例。治療2箇週期後，通過超聲造影對兩組治療效果進行評估。結果聯閤組中49例（51.6%）腫瘤完全滅活，46例腫瘤滅活不全；而TACE組中8例（25.4%）腫瘤完全滅活，TACE組腫瘤完全滅活率顯著低于聯閤組（ P<0.05）。結論 TACE聯閤PMCT治療中晚期肝癌療效優于單用TACE治療。
목적탐토간동맥전새화료（ TACE）연합미파소융치료（ PMCT）중만기간암적림상료효。방법선취아원2007년1월~2012년1월127례단발종류직경5~8 cm적중만기간암환자，분위TACE조32례화연합조（ TACE+PMCT）95례。치료2개주기후，통과초성조영대량조치료효과진행평고。결과연합조중49례（51.6%）종류완전멸활，46례종류멸활불전；이TACE조중8례（25.4%）종류완전멸활，TACE조종류완전멸활솔현저저우연합조（ P<0.05）。결론 TACE연합PMCT치료중만기간암료효우우단용TACE치료。
Objective To investigate the clinical effects of hepatic arterial chemoembolization( TACE )combined with percutaneous microwave coagulation therapy( PMCT)on advanced liver cancer. Methods Total 127 medium-advanced liver cancer patients with single tumor diameter of 5-8 cm receiving treatment in our hospital from Jan. of 2007 to Jan. of 2012 were selected and divided into TACE group(n=32)and combination group(TACE+PMCT)(n=95). After two cycles of treatment,contrast-enhanced ultrasound was used to evaluate the curative effects of both groups. Results Total 49 patients in the combination group had the tumor completely inactivated(51. 6%)and 46 ones had the tumor incompletely inactivated,while eight ones in TACE group had the tumor completely inactivated(25. 4%). The rate of complete inactivation of the patients in TACE group was significantly lower than that in the combination group(P<0. 05). Conclusion The curative effect of TACE combined with PMCT is better than that of only use of TACE in treatment of advanced liver cancer.
